As we await the FDA’s results to decide on the outcome of the aducanumab trial, this year is clearly a critical year for all those working on neurodegenerative R&D.

Back with a bang, in an all new digital format, the 9^th Neurodegenerative Drug Development Summit is the industry’s definitive and unrivalled forum focused on revealing hot and promising pockets of innovation in drug discovery for neurodegenerative diseases and combating translational challenges by shining a light on pioneering companies leading the way to meet this dire medical need.

Building on the success of last year’s meeting, this year’s program showcases new biotechs trailblazing this space and will put the spotlight on the latest scientific advances in terms of diverse targets, novel modalities and innovative trial design.

Across 3 action-packed, case-study driven days and 2 parallel tracks of learning, we present the opportunity to join us online in 2021 to overcome technical and operational challenges preventing you and your team from translating promising preclinical research into evidenced clinical benefit.

Whether you are working in a team dedicated to Parkinson’s, Alzheimer’s, ALS, Frontotemporal Dementia or a rare neurodegenerative disorder, join this intimate, industry-led forum to not only to learn from those spearheading this space, but to network and build meaningful partnerships with over 180 neurodegenerative drug development experts. After all, collaboration in this industry is pivotal.